Death rates from prostate cancer predicted to decline overall in EU but rise in Poland

April 19, 2020

Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment, according to new research published in the leading cancer journal Annals of Oncology [1] today (Monday).

In the latest predictions for cancer deaths in the EU for 2020, researchers led by Carlo La Vecchia (MD), Professor at the School of Medicine, University of Milan (Italy), show that since 2015 there has been a 7% reduction in deaths from prostate cancer, with a predicted age standardised rate for 2020 of 10 men per 100,000 of the population [2]. A total of 78,800 men are predicted to die from the disease this year.

Poland is the only EU country where death rates from prostate cancer are not falling; instead the researchers predict a rise of 18% since 2015: an age standardised death rate of 15 per 100,000 men, with 6,100 men predicted die from it by the end of 2020.

Prof La Vecchia said: "Poland started with the lowest death rate from prostate cancer between 1970 to 1974, but then rates increased up to the year 2000, stabilised for a while and then rose again up to 2020. So Polish prostate cancer death rates are now the highest predicted. This is difficult to explain. It is possible that the recent relatively high rates are due to delayed adoption of modern diagnosis and treatment.

"Across the EU as a whole, the key message from these prostate cancer death rates is to adopt up-to-date surgery and radiotherapy techniques, together with newer androgen deprivation therapy. This may have a relevant impact on prostate cancer mortality even in the absence of cure, since a proportion of elderly men may survive long enough to die from other causes. The prostate specific antigen test, PSA, may also play a role, but it is difficult to quantify this at present. It has major impact on incidence, but an unquantified impact on death rates."

Although prostate cancer death rates are declining, the actual numbers of men dying from the disease are predicted to increase due to the EU's aging populations. In 2015 74,998 died from the disease, compared to 78,800 predicted to die in 2020.

This pattern is seen in the predicted death rates and actual numbers of deaths for all cancers in the EU and for the ten major cancers analysed in more detail. The researchers predict that death rates from all cancers will decline by 5% in men and 4% in women between 2015 and 2020, giving death rates of 130 per 100,000 and 82 per 100,000 respectively; but the predicted numbers of deaths will increase by 5%, reaching 1,428,000 by the end of this year: 798,700 in men and 630,100 in women.

The researchers looked at cancer death rates in the EU 28 Member States [3] as a whole and also in the six largest countries - France, Germany, Italy, Poland, Spain and the UK - for all cancers, and, individually, for stomach, intestines, pancreas, lung, breast, uterus (including cervix), ovary, prostate, bladder and leukaemias for men and women [4]. This is the tenth consecutive year the researchers have published these predictions. Prof La Vecchia and his colleagues collected data on deaths from the World Health Organization from 1970 to 2016.

Prof La Vecchia said: "Overall cancer death rates in Poland are predicted to be 28% higher than the EU average for men and 21% for women. This gap between central-eastern and western Europe is due to patterns in tobacco consumption, but also to a slower adoption of up-to-date prevention, disease management and treatment.

"In the EU as a whole, cancer death rates for men are falling. More than half of this is due to declines in death rates from tobacco-related cancers. These include not only lung cancer, which accounts for over a third of the decline, but also cancers such as head and neck and bladder cancers. In other words, it is due to fewer European men smoking, which started a few decades ago."

However, death rates are rising in women for cancers of the lung and pancreas; there is a predicted increase of 6% in death rates for lung cancer between 2015 and 2020 (15.1 deaths per 100,000 and about 100,000 deaths) and an increase of 1.2% in pancreatic cancer (5.6 deaths per 100,000 and 46,200 deaths). Death rates from lung cancer among women overtook those from breast cancer in 2016 and this trend is continuing. The researchers predict the death rate from breast cancer this year will be 13.5 per 100,000 (95,900 deaths), down 7.3% from 2015.

Prof La Vecchia said: "Death rates from lung cancer in women have been increasing persistently in the EU over the past decade, although the rate of increase is now slowing. Between 2010 and 2020 female lung cancer rates in the EU increased from about 13 to over 15 per 100,000. In the absence of effective intervention on tobacco smoking in women, the overall rate will probably reach 16 or 17 per 100,000 in 2030 and only level off in the subsequent decade."

Co-author, Dr Eva Negri, a senior researcher at the University of Milan, said: "There are some differences between countries in female lung cancer death rates. For instance, French and Spanish rates are rising more than British or Italian ones. This again reflects smoking habits in different generations of women in various countries and underlines the importance of convincing women to give up smoking, not only in Poland or the UK, which now have the highest rates, but also in France or Spain, which still have relatively low overall rates. This will help to control the persistent epidemic of lung and other tobacco-related cancers in women.

"Tobacco remains the main cause of cancer mortality in Europe, accounting for around 20% of total predicted cancer deaths; the marked decline in the deaths in men compared to women reflects the differences in past smoking habits between the two sexes."

The researchers predict that compared to a peak rate of cancer deaths in 1988, over 5.7 million cancer deaths will be avoided in the EU in the 32-year period up to 2020. In 2020 alone, a total of 406,000 deaths from cancer are predicted to be averted (282,000 in men and 124,000 in women). For prostate cancer, 462,000 deaths will have been prevented over the 32-year period and 40,000 in 2020 alone.

Co-author, Fabio Levi (MD), Emeritus Professor at the Faculty of Biology and Medicine, University of Lausanne (Switzerland), said: "Pancreatic cancer trends remain unfavourable across Europe. Control of tobacco and action on overweight, obesity and diabetes could improve such trends. No relevant advances have been observed in the diagnosis and treatment of this cancer, which has a particularly poor prognosis. Therefore, greater investment in research is required."
[1] "European cancer mortality predictions for the year 2020 with focus on prostate cancer", by G. Carioli et al. Annals of Oncology. doi:

[2] Age-standardised rates per 100,000 of the population reflect the annual probability of dying.

[3] At the time of this analysis, the EU had 28 member states, with Croatia joining in 2013. However, Cyprus was excluded from this analysis due to excessive missing data.

[4] The paper contains individual tables of cancer death rates for each of the six countries.

European Society for Medical Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to